Beth Israel Deaconess Medical Center

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Beth Israel Deaconess Medical Center sits in the top decile of US sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count).

488 total trials 66 currently recruiting 321 completed early-phase tilt top decile by trial count

Beth Israel Deaconess Medical Center: 488 sponsored US clinical trials, 66 recruiting.

Beth Israel Deaconess Medical Center sponsors 488 registered US clinical trials on ClinicalTrials.gov, 66 of them currently recruiting, and 321 completed. 45 of these trials are in Phase 3-4 (later-stage) and 144 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Breast Cancer, with 8 trials.

Top-decile sponsor footprint

Beth Israel Deaconess Medical Center ranks in the top decile of sponsors by registered trial count (#75 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 51/100

321 of 380 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

488 total, page 7 of 10

COMPLETED NA

Evaluation of Ubiquinol on Mitochondrial Oxidative Capacity in Statin Patients Using 31PMRS

NCT01702987

COMPLETED Phase 2

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

NCT01670500

COMPLETED Phase 2

Ubiquinol (Reduced COQ10) for Patients With Sepsis

NCT01948063

TERMINATED Phase 1

Sleep Effectiveness and Insulin and Glucose Homeostasis

NCT01887691

COMPLETED NA

Weight Loss Study-Mechanism Underlying the Improvement of Insulin Resistance in Response to Weight Loss

NCT01780870

COMPLETED NA

Tai Chi After Pulmonary Rehabilitation in Patients With COPD: A Randomized Trial

NCT01998724

COMPLETED

Qualitative Study of Topical Mesalamine Adherence in Patients With Ulcerative Colitis(UC)

NCT01678300

COMPLETED NA

Enhancement of Brain Circuit of Inhibitory Control in Obese Patients Undergoing Gastric Banding

NCT01632280

COMPLETED NA

Brain Imaging, Cognitive Enhancement and Early Schizophrenia

NCT01561859

COMPLETED Early Phase 1

Quercetin PK/PD Study in Healthy Adults and Patients With Hypercoagulable States

NCT01722669

COMPLETED NA

Effects of S. Boulardii and Amoxicillin/Clavulanate on Gut Microbiota

NCT01473368

COMPLETED Phase 2

Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism

NCT01653132

COMPLETED Phase 4

Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRI

NCT01562678

COMPLETED Phase 2

Evaluating the Effectiveness of Intravenous Immunoglobulin Therapy in Autoimmune Autonomic Ganglionopathy

NCT01522235

COMPLETED NA

Seizure Activity in Alzheimer's Disease

NCT01554683

COMPLETED NA

Therapeutic Efficacy of Transcranial Magnetic Stimulation in Schizophrenia

NCT01551979

TERMINATED Phase 2

Randomized Study of Stereotactic Body Radiotherapy vs. Conventional Radiation for Spine Metastasis

NCT01525745

COMPLETED NA

Effect of Increased Free Fatty Acids on Leptin Function

NCT01520454

TERMINATED Phase 2

PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine

NCT01441765

COMPLETED Phase 1

Aerosol Inhalation Treatment for Dyspnea

NCT01440764

COMPLETED NA

Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness

NCT01462279

TERMINATED Phase 1

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

NCT01397734

TERMINATED Phase 1

Hemodynamic Response of Neuropathic And Non-Neuropathic POTS Patients To Adrenoreceptor Agonist And Antagonist

NCT03070730

COMPLETED

Kidney Donor Outcomes Cohort (KDOC) Study

NCT01427452

COMPLETED NA

Repeated Challenge of Insufficient Sleep: Endothelial Effects

NCT01523535

COMPLETED NA

Effects of Pre-, Pro- & Anti-biotics on Gut Microbiota

NCT01414010

COMPLETED NA

Repeating Patterns of Sleep Restriction and Recovery

NCT01523691

COMPLETED NA

A Clinical Study to Limit Physiologic Intestinal FDG Uptake Uptake on PET-CT Scans

NCT01542541

COMPLETED Early Phase 1

Real-Time Near-infrared (NIR) Mapping of Sentinel Lymph Nodes in Breast Cancer

NCT01468649

COMPLETED Phase 2

N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis

NCT01354132

COMPLETED

Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease

NCT01349504

COMPLETED Phase 2

BEAM COPD: Breathing, Education, Awareness and Movement in Chronic Obstructive Pulmonary Disease (COPD)

NCT01551953

COMPLETED Phase 2

Coenzyme Q10 in Post-Cardiac Arrest Cerebral Resuscitation

NCT01319110

COMPLETED NA

Effects of a Combined Transcranial Magnetic Stimulation (TMS) and Cognitive Training in Alzheimer Patients

NCT01504958

COMPLETED NA

Effect on Acetaminophen Metabolism by Liquid Formulations

NCT01246713

COMPLETED Phase 2

Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer

NCT01299038

COMPLETED

JC Virus Reactivation in Multiple Sclerosis

NCT02004444

COMPLETED

Effectiveness of Open and Robotic Prostatectomy

NCT01325506

COMPLETED

Dance Exercise as Novel Complementary Therapy for Parkinson's Disease

NCT01163344

TERMINATED NA

The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia

NCT01146457

TERMINATED NA

Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging for the Evaluation of Response to Therapy in Metastatic Renal Cell Carcinoma

NCT00953446

COMPLETED Phase 2

Enhancement of Cerebral Vasoreactivity and Cognition by Intranasal Insulin in Type 2 Diabetes

NCT01206322

COMPLETED NA

rTMS for Motor and Mood Symptoms of Parkinson's Disease

NCT01080794

COMPLETED Phase 2

Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission

NCT01096602

TERMINATED NA

Ketorolac Effects on Post-operative Pain and Bone Healing

NCT01133639

COMPLETED Phase 2

Study of Leptin for the Treatment of Hypothalamic Amenorrhea

NCT00130117

COMPLETED NA

Singing in Groups for Parkinson's Disease; A Pilot Study of Group Singing Therapy for PD-related Voice/Speech Impairment

NCT01163331

COMPLETED

Comparing Google With A Focused Diabetes Search Engine

NCT01080976

COMPLETED NA

Improvement of Insulin Resistance After Bariatric Surgery

NCT03853590

COMPLETED NA

Glycemic Index and Brain Function

NCT01064778

← Previous Page 7 of 10 Next →

Phase Distribution

PhaseTrial count
Phase 1 53
Phase 2 91
Phase 3 13
Phase 4 32

What is open in the Beth Israel Deaconess Medical Center pipeline

66 recruiting of 488 indexed (14% open); 321 completed (66%).

Phase mix: 45 late (III/IV) vs 144 early (I/II) (early-phase heavy).

Top condition: Breast Cancer (8 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Beth Israel Deaconess Medical Center: open-pipeline peers nationwide

Peers matched on 488 registered trials and 14% open enrollment, not the therapeutic-area sidebar.

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 8%10%12%14%16%18% Total trials Recruiting share Beth Israel Deaconess Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Fred Hutchinson Cancer CenterNational Heart, Lung, and Blood Institute (NHLBI)H. Lee Moffitt Cancer Center and Research InstituteCase Comprehensive Cancer CenterWayne State UniversityUniversity of MichiganAlbany Medical College
Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Beth Israel Deaconess Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 488 trials (± recruiting share)

Sponsors near 14% open enrollment (± trial volume)

What to do with this Beth Israel Deaconess Medical Center page

488 registered trials is a research-attention snapshot, not an endorsement of Beth Israel Deaconess Medical Center or any single study.

  • 66 of Beth Israel Deaconess Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Breast Cancer is the condition Beth Israel Deaconess Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Breast Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Beth Israel Deaconess Medical Center pipeline card: 488 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.